Остановка "Гепатит С"
( Информация о гепатите С, диагностика гепатита С, лечение гепатита С, жизнь с гепатитом С...)

Гепатит С и ВИЧ-инфекция: тактика ведения пациентов с сочетанной инфекцией.


Библиография.

1. Salmon-Ceron D et al. Liver disease as a major cause of death among HIV-infected patients: roles of hepatitis C and B viruses and alcohol. Journal of Hepatology, 2005, 42: 799-805.

2. Carrat F et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV- infected patients: a randomized controlled trial. JAMA, 2004, 292:2839-2848.

3. Torriani FJ et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. The New England Journal of Medicine, 2004, 351:438-450.

4. Chung RT et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. The New England Journal of Medicine, 2004, 351:451-459.

5. Laguno M et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS, 2004, 18:F27-F36.

6. Rockstroh JK et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. Journal of Infectious Diseases, 2005, 15, 192(6):992-1002.

7. Rockstroh JK et al. F12/4: influence of hepatitis C coinfection on HIV disease progression within the EUROSIDA Cohort. Ninth European AIDS Conference (EACS): 1st EACS Resistance and Pharmacology Workshop, Warsaw, 25- 29 October 2003.

8. Sherman KE et al. Prevalence of antibodies to hepatitis C virus in patients infected with the human immunodeficiency virus. Journal of Infectious Diseases, 1991, 163:414-415.

9. Salmon-Ceron et al. Hospitalized HIV-HCV coinfected patients. A French national survey made in June 2001. Medecine et maladies infectieuses, 2003, 33:78-83.

10. Saillour F et al. Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. BMJ, 1996, 313:461-464.



11. Hayashi PH et al. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. Journal of Medical Virology, 1991, 33: 177-180.

12. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected patient. Clinical Liver Disease, 2003, 7(1):179-194.

13. Alter MJ. Epidemiology of viral hepatitis. Journal of Hepatology, 2006, 44(S1):S6-S9.

14. Quaglio GL et al. Hepatitis C virus infection: prevalence, predictor variables and prevention opportunities among drug users in Italy. Journal of Viral Hepatitis, 2003, 10(5):394-400.

15. D'Oliveira A Jr et al. Prevalence and sexual risk of hepatitis C virus infection when human immunodeficiency virus was acquired through sexual intercourse among patients of the Lyon University Hospitals, France, 1992-2002. Journal of Viral Hepatitis, 2005, 12(3):330-332.

16. Chaix M-L et al. Homosexually transmitted HCV acute infection related to a clustered genotype 4 HCV in HIV-1- infected men and inefficacy of early antiviral therapy. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, 22-25 February 2005 (Abstract 122).

17. Ackerman Z, Ackerman E, Paltiel O. Interfamilial transmission of hepatitis C virus: a systematic review. Journal of Viral Hepatology, 2000, 7(2):93-103.

18. Jager J et al., eds. Hepatitis C and injecting drug use: impact, costs and policy options. Lisbon, European Monitoring Centre for Drugs and Drug Addiction, 2004 (EMCDDA Monographs).

19. Franciscus A. HCV Genotype and quasi-species. HCSPFACT Sheet. Hepatitis C Support Project, 2006 (http://www.hcvadvocate.org/hepatitis/factsheets_pdf/genotype_FS.pdf, accessed 28 February 2006).

20. Simmonds et al. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. Journal of Hepatology, 1996, 24(5):517-524.

21. Zeuzem S et al. Risk factors for the transmission of hepatitis C. Journal of Hepatology, 1996, 24(2 Suppl.):3-10.

22. Salmon D et al. Therapeutic management of hepatitis and HIV infection in coinfected patients: results of a survey performed before the 2005 Consensus Conference. Journal of Hepatology, 2006, 44(S1):S2-S5.

23. Poynard T et al. A comparison of fibrosis progression in chronic liver diseases. Journal of Hepatology, 2003, 38:257-265.

24. Grebely J et al. Effect of HIV coinfection on spontaneous clearance of hepatitis C virus (HCV) in the downtown Eastside of Vancouver. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, 24-27 July, 2005 (Abstract No. TuPe1.1C18).

25. Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection. Journal of Hepatology, 2006, 44(S1):S28-S34.

26. Benhamou Y et al. Liver fibrosis progression in HIV-HCV coinfected patients. The Multivirc Group. Hepatology, 1999, 30:1054-1058.

27. Forns X, Costa J. HCV virological assessment. Journal of Hepatology, 2006, 44(S1):S40-S43.

28. Thio CL et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. Journal of Clinical Microbiology, 2000, 38(2):575-577.

29. Van Asten L, Prins M. Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression. AIDS, 2004, 18(17):2319-2324.

30. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Safety, 2005, 28(1):53-66.

31. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology, 2002, 36(5 Suppl. 1):S65-S73.

32. Thomas D. Options for treatment of hepatitis C in HIV-infected persons. Journal of Hepatology, 2006, 44(Suppl. 1):S40-S43.

33. Fried MW et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine, 2002, 347(13):975-982.

34. Torriani FJ et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. The New England Journal of Medicine, 2004, 351(5):438-450.

35. Leruez-Ville M et al. Large-scale analysis of hepatitis C virus serological typing assay: effectiveness and limits. Journal of Medical Virology, 1998, 55(1):18-23.

36. Pugh RNH et al. Preoperative assessment of patients with liver disease. British Journal of Surgery, 1973, 60:646-649.

37. Bravo AA, Sheth SG, Chopra S. Liver biopsy. The New England Journal of Medicine, 2001, 344(7):495-500.

38. Friedman SL. Score Metavir Evaluation of fibrosis and hepatitis C. American Journal of Medicine, 1999, 107(6B):27S-30S.

39. Kelleher TB, Afdha NL. Assessment of liver fibrosis in coinfected patients. Journal of Hepatology, 2006, 44(S1):S126-S131.

40. Nunes D et al. HIV infection does not affect the performance of non-invasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. Journal of Acquired Immune Deficiency Syndrome, 2005, 4(5):538-544).

41. Ce Ledinghen V et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus- coinfected patients. Journal of Acquired Immune Deficiency Syndrome, 2006, 41(2):175-179.

42. Nunes D et al. HIV infection does not affect the performance of non-invasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. Journal of Acquired Immune Deficiency Syndrome, 2005, 40(5):538-544.

43. Alberti A et al. Short statement of the first European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Coinfected Patients. Journal of Hepatology, 2005, 42(5):615-624.

44. Hassan MM. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 2002, 36:1206-1213.

45. Samet JH et al. A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. Antiviral Therapy, 2005, 10(1):83-93.

46. European STD Guidelines. International Journal of STD & AIDS, 2001, 12(10) Supplement 3.

47. Mast EE et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005, 192(11):1880-1889.

48. Kochhar DM, Penner JD, Knudsen TB. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicology and Applied Pharmacology, 1980, 52(1):99-112.

49. Hadziyannis SJ et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 2004, 140(5):346-355.

50. Marrache F et al. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. Journal of Viral Hepatology, 2005, 12(4):421-428.

51. Vogel M et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. Journal of Viral Hepatology, 2005, 12(2):207-211.

52. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palù G, Reiss P, Thiebaut R, Weiland O, Yazdanpanah Y, Zeuzem S (The ECC Jury). Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients, 21 March 2005. Journal of Hepatology, 2005, 42(5):615-624.

53. Perez-Olmeda M et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS, 2003, 17(7):1023-1028.

54. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach: 2003 revision. Geneva, World Health Organization, 2004.

55. Patel SM et al. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. Journal of Acquired Immune Deficiency Syndrome, 2004, 35(2):120-125.

56. Moreno A et al. High rate of didanosine-related mitochondrial toxicity in HIV-HCV coinfected patients receiving didanosine. Antiviral Therapy, 2004, 9:133-138.

57. Salmon-Ceron D et al. Mitochondrial toxic effects of ribavirin. The Lancet, 2001, 357:1803.

58. Lafeuillade A, Hittinger G, Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV-HCV coinfection. The Lancet 2001, 357:280-281.

59. Mauss S. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS, 2004, 18(13):F21-25.

60. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS, 1998, 12:1256.

61. Sulkowski MS et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA, 2000, 283:74-80.

62. Wit FW et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. Journal of Infectious Diseases, 2002, 186:23-31.

63. Aceti A et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. Journal of Acquired Immune Deficiency Syndrome, 2002, 29:41-48.

64. Torti C et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV- HCV coinfected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infectious Diseases, 2005, 5:58.

65. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetic in hepatitis with hepatic dysfunction. Clinical Infectious Diseases, 2005, 40:174-181.

66. Salmon D, Taburet AM. Antiretroviral agents in HIV-infected patients with cirrhosis. Actuality on HIV in 2005. La Presse medicale, 2005, 34, 10(Suppl. 1):S451-S52, 45.

67. Regazzi M et al. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrobial Agents and Chemotherapy, 2005, 49(2):643-649.

68. Arribas JR et al. Lopinavir/Ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK study). Journal of Acquired Immune Deficiency Syndrome, 2005, 40(3):280-287.

69. Veronese L et al. Single-dose pharmacokinetics of Amprenavir, a human Immunodeficiency Virus Type 1 protease inhibitor in subjects with normal or impaired hepatic function. Antimicrobial Agents and Chemotherapy, 2002, 821- 826.

70. Dominguez S et al. The HEPADOSE Study: evaluation of protease inhibitors and non-nucleoside analogue plasma concentrations in HIV/HCV and HIV-infected patients. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio Janeiro, 24-27 July 2005 (Abstract No. WePp0305; http://www.aegis.com/conferences/IASHIVPT/2005/WePp0305.pdf, accessed 28 February 2006).

71. Chutaputti A. Adverse effects and other safety aspects of the hepatitis C antivirals. Journal of Gastroenterology and Hepatology, 2000, 15(Suppl.E):156-163.

72. Sulkowski MS et al. Epoetin alfa once weekly improves anaemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. Journal of Acquired Immune Deficiency Syndrome, 2005, 39(4):504-506.

73. European Medicine Agency. Dosage adjustment of ribavirin Rebetol. London, 2006 (www.emea.eu.int/humandocs/PDFs/EPAR/Rebetol/H-246-PI-en.pdf, accessed 28 February 2006).

74. European Medicine Agency. Dosage adjustment interferon Pegasys and Viraferon Peg. London, 2006 (http://www.emea.eu.int/humandocs/PDFs/EPAR/pegasys/H-395-PI-en.pdf and http://www.emea.eu.int/humandocs/PDFs/EPAR/Viraferonpeg/H-329-PI-en.pdf, accessed 28 February 2006).

75. Moncoucy X et al. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterology and Clinical Biology, 2005, 29(4):339-345.

76. Puoti M et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS, 2004, 18(17):1-9.

77. Hoofnagle JH. Hepatocellular carcinoma: summary and recommendations. Gastroenterology, 2004, 127:S319-S323.

78. Samonakis DN et al. Management of portal hypertension. Postgraduate Medical Journal, 2004, 80(949):634-641.

79. Vogt MW et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science, 1987, 235:1376-1379.

80. Sim SM et al. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. AIDS Research and Human Retroviruses, 1998, 14:1661-1667.

81. Salmon-Ceron D et al. Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial. Clinical Infectious Diseases, 2003, 36:1295-1304.

82. Perronne C. Antiviral hepatitis and antiretroviral drug interactions. Journal of Hepatology, 2006, 44(S1):S119-S125.

83. Baba M et al. Ribavirin antagonizes inhibitory effects of pyrimidine 2’,3’-dideoxynucleosides but enhances inhibitory effects of purine 2’, 3’- dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrobial Agents and Chemotherapy, 1987, 31:1613-1617.

84. Hoggard PG, et al. Effects of drugs on 2’,3’-dideoxy-2’,3’-didehydrothymidine phosphorylation in vitro. Antimicrobial Agents and Chemotherapy, 1997, 41:1231-1236.

85. Balzarini J et al. Mechanisms of the potentiating effect of ribavirin on the activity of 2’,3’-dideoxyinosine against human immunodeficiency virus. Journal of Biological Chemistry, 1991, 266:21:509-514.

86. Harvie P et al. Ribavirin potentiates the efficacy and toxicity of 2’,3’-dideoxyinosine in the murine acquired immunodeficiency syndrome model. Journal of Pharmacology and Experimental Therapeutics, 1996, 279:1009-1017.

87. Japour AJ et al. A phase-1 study of the safety, pharmacokinetics, and antiviral activity of combination of didanosine and ribavirin in patients with HIV-1 disease. Journal of Acquired Immune Deficiency Syndrome, 1996, 13:235-246.

88. Ungo JR et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. American Journal of Respiratory and Critical Care Medicine, 1998, 157(6 Pt 1):1871-1876.

89. Yee D et al. Incidence of serious side-effects from first-line antituberculosis drugs among patients treated for active tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167(11):1472-1477.

90. Hollingsworth RC et al. Serum HCV RNA levels assessed by quantitative NASBA: stability of viral load over time, and lack of correlation with liver disease. The Trent HCV Study Group. Journal of Hepatology, 1996, 25(3):301-306.

91. Forns X, Bukh J. Methods for determining the hepatitis C virus genotype. Viral Hepatitis Reviews, 1998, 4:1-19.

92. Wai CT et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 2003, 38(2):518-526.

93. Forns X et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology, 2002, 36(4 Pt 1):986-992.

94. Ziol M et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology, 2005, 41(1):48-54.

95. Imbert-Bismut F et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. The Lancet, 2001, 357(9262):1069-1075.

96. Castera L et al. Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 2005, 128(2):343-350.

97. Patel K et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. Journal of Hepatology, 2004, 41(6):935-942.

98. Kelleher TB et al. Prediction of hepatic fibrosis in HIV/HCV coinfected patients using serum fibrosis markers: the SHASTA index. Journal of Hepatology, 2005, 43(1):78-84.

99. Rosenberg WM et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology, 2004, 127(6):1704-1713.

100. Ewing JA. Detecting alcoholism: the CAGE questionnaire. JAMA, Journal of the American Medical Association, 1984, 252:1905-1907.

101. Babor TF et al. AUDIT, the Alcohol Use Disorders Identification Test: guidelines for use in primary care (2nd ed.). Geneva, World Health Organization, 2001 (http://whqlibdoc.who.int/hq/2001/WHO_MSD_MSB_01.6a.pdf, accessed 29 March 2006).

102. Smukler AJ, Ratner L. Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients. Current Opinion in Oncology, 2002, 14:538-542.

103. Garcia-Samaniego J et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. American Journal of Gastroenterology, 2001, 96:179-183.

104. Davila JA et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology, 2004, 127:1372-1380.

105. Bruix J et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of Hepatology, 2001, 3:421-430.

106. Daniele B et al. alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology, 2004, 127:S108-S112.

107. Samuel D et al. Liver transplantation in patients with HIV infection. Journal of Hepatology, 2003, 39(1):3-6.

108. Tzakis AG et al. Transplantation in HIV + patients. Transplantation, 1990, 49:354-358.

109. Miro JM et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain: March 2005. Enfermedades Infecciosas y Microbiologia Clinica, 2005, 23(6):353-362.

110. Ragni MV et al. Survival of human immunodeficiency virus-infected liver transplant recipients. Journal of Infectious Diseases, 2003, 188(10):1412-1420.

111. Bhopale GM, Nanda RK. Emerging drugs for chronic hepatitis C. Hepatology Research: the Official Journal of the Japan Society of Hepatology, 2005, 32(3):146-153.

112. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature, 2005, 436(18):953-960.





 

Реклама: